Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Keyphrases

• Alzheimer's Disease 100%
• Comorbidity 100%
• Beneficial Effects 100%
• Acetylcholinesterase Inhibitors (AChEI) 100%
• Polypharmacy 50%
• Gastrointestinal 25%
• Medical Conditions 25%
• Dementia 25%
• High Risk 25%
• Cost Reduction 25%
• Elderly Patients 25%
• Cognitive Impairment 25%
• Dementia with Lewy Bodies 25%
• Inhibitor Treatment 25%
• Vascular Dementia 25%
• Medication Compliance 25%
• Multiple Symptoms 25%
• Early Symptoms 25%
• Adverse Drug Events 25%
• Causes of Dementia 25%
• Rivastigmine 25%
• Galantamine 25%
• Aricept 25%
• Exelon 25%
• Excessive Polypharmacy 25%
• Donepezil 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer's Disease 100%
• Cholinesterase Inhibitor 100%
• Comorbidity 100%
• Polypharmacy 75%
• Rivastigmine 50%
• Donepezil 50%
• Galantamine 50%
• Cognitive Defect 25%
• Adverse Drug Reaction 25%
• Multiinfarct Dementia 25%
• Diffuse Lewy Body Disease 25%